Table 2. Univariate analyses of patient and tumor characteristics for survival.

	Event-free survival						Overall survival
Variable	N used	N event	HR	95% Lower	95% Upper	p-value	N event	HR	95% Lower	95% Upper	p-value
Time from 1st chemo to 3F8	170	75	0.906	0.839	0.978	0.012	46	0.938	0.856	1.029	0.179
Time from ASCT/last chemo to 3F8	170	75	0.726	0.553	0.954	0.022	46	0.889	0.666	1.188	0.426
ASCT (Y vs N)	170	75	0.68	0.413	1.12	0.13	46	0.991	0.546	1.797	0.975
MYCN-amplified (Y vs N)	162	74	0.747	0.473	1.179	0.21	46	0.681	0.380	1.219	0.196
Ultra-High-Risk (Y vs N)	170	75	1.221	0.759	1.966	0.41	46	1.175	0.640	2.157	0.602
HAMA (Y vs N)*	170	75	1.169	0.687	1.989	0.564	46	0.536	0.279	1.022	0.058
High-Dose 3F8 (Y vs N)	170	75	1.507	0.791	2.871	0.212	46	2.220	0.902	5.467	0.083
Pre-MRD (Y vs N)	170	75	1.009	0.617	1.648	0.972	46	1.269	0.696	2.313	0.436
Post-MRD (Y vs N)*	165	72	4.997	2.894	8.627	< 0.001	43	4.304	2.232	8.301	< 0.001
FcGR2a
HR vs HH	170	75	0.679	0.401	1.149	0.149	46	0.702	0.362	1.362	0.295
RR vs HH	170	75	0.865	0.469	1.594	0.642	46	0.748	0.336	1.666	0.477
FcGR3a
VF vs FF	170	75	0.654	0.347	1.234	0.19	46	0.794	0.339	1.86	0.596
VV vs FF	170	75	0.646	0.332	1.258	0.199	46	0.862	0.357	2.08	0.741
KIR (Y vs N)	170	75	0.864	0.528	1.411	0.558	46	0.953	0.501	1.81	0.882
KIR 2DL1 (Y vs N)	170	75	0.973	0.617	1.534	0.907	46	1.37	0.766	2.45	0.288
KIR 2DL2 2DL3 (Y vs N)	170	75	0.754	0.346	1.643	0.478	46	0.525	0.163	1.693	0.281
KIR 3DL1 (Y vs N)	170	75	0.615	0.371	1.019	0.059	46	0.631	0.332	1.2	0.16
Trial (09–158/159 vs03–077)	170	75	1.370	0.735	2.552	0.321	46	1.883	0.764	4.642	0.169

^*time-dependent variable